These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 28478430)

  • 21. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 10 years after implementation of TRIPS obligations in India.
    Pawar MD
    Pharm Pat Anal; 2015; 4(3):147-59. PubMed ID: 26030078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A trade agreement's impact on access to generic drugs.
    Shaffer ER; Brenner JE
    Health Aff (Millwood); 2009; 28(5):w957-68. PubMed ID: 19706626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.
    Okeniyi SO; Okereke M
    Pharm Pat Anal; 2022 Sep; 11(5):131-133. PubMed ID: 36177777
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of TRIPS on innovation and exports: a case study of the pharmaceutical industry in India.
    Malhotra P
    Indian J Med Ethics; 2008; 5(2):61-5. PubMed ID: 18624153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
    Cohen JC; Illingworth P
    Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PATENTING OF MEDICINAL PRODUCTS: THE EXPERIENCE OF IMPLEMENTATION OF THE FLEXIBLE PROVISIONS OF THE TRIPS-PLUS AGREEMENT BY FOREIGN COUNTRIES AND THE FUNDAMENTAL PATENT REFORM IN UKRAINE.
    Deshko L
    Georgian Med News; 2018 Sep; (282):161-166. PubMed ID: 30358562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing drugs for the developing world: an economic, legal, moral, and political dilemma.
    Resnik DB
    Dev World Bioeth; 2001 May; 1(1):11-32. PubMed ID: 12870505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):33-42. PubMed ID: 25138241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Big-pharmaceuticalisation: clinical trials and Contract Research Organisations in India.
    Sariola S; Ravindran D; Kumar A; Jeffery R
    Soc Sci Med; 2015 Apr; 131():239-46. PubMed ID: 25476783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system.
    Kesselheim AS
    AAPS J; 2007 Aug; 9(3):E306-11. PubMed ID: 17915832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.